Evaluation of the pressure variation and lifetime of a newly developed asymmetric triacetate membrane hemofilter

DOI Web Site
  • Ono Kouhei
    Department of Medical Engineering Center, Oita University Hospital
  • Inoue Takamitsu
    Department of Medical Engineering Center, Oita University Hospital
  • Endo Chizuru
    Department of Medical Engineering Center, Oita University Hospital
  • Nakashima Tatsunori
    Department of Medical Engineering Center, Oita University Hospital
  • Makino Takenori
    Department of Anesthesiology and Intensive Care, Oita University Hospital
  • Ohchi Yoshifumi
    Department of Anesthesiology and Intensive Care, Oita University Hospital
  • Yasuda Norihisa
    Department of Anesthesiology and Intensive Care, Oita University Hospital
  • Goto Koji
    Department of Anesthesiology and Intensive Care, Oita University Hospital
  • Kitano Takaaki
    Department of Anesthesiology and Intensive Care, Oita University Hospital

Bibliographic Information

Other Title
  • 新規hemofilterであるasymmetric triacetate膜の回路内圧の経時変化および膜寿命の評価
  • シンキ hemofilter デ アル asymmetric triacetateマク ノ カイロ ナイアツ ノ ケイ ジヘンカ オヨビ マク ジュミョウ ノ ヒョウカ

Search this article

Abstract

<p>While the asymmetric triacetate (ATA) membrane, a novel hemofilter, has the potential to achieve an extended membrane lifetime given its high biocompatibility, this has not been investigated in clinical settings. The present study aimed to determine the stability of internal circuit pressure and membrane lifetime of the ATA membrane in clinical use with a retrospective case-control design. Patients who underwent continuous renal replacement therapy (CRRT) after cardiac surgery due to acute kidney injury for more than 24 hours were divided into two groups based on the type of membrane used: the ATA group (n=15) and the cellulose triacetate (CTA) group (n=14). Patient characteristics, intra-circuit pressure variations, and membrane lifetime at 4, 8, 12, and 24 hours from the start of CRRT were compared between the two groups. There was no significant difference in patient characteristics except hematocrit. The rate of change in TMP at 24 hours from the start of CRRT were significantly higher in the CTA group. There was no significant difference in membrane lifetime. These results suggest that the ATA membrane has more stable circuit pressure compared to the CTA membrane in clinical use. A future study will be necessary to observe and compare these membranes for more than 24 hours. </p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top